Keyphrases
Breast Cancer
66%
Male Breast Cancer
55%
Breast Cancer Patients
43%
Mastectomy
41%
National Surgical Quality Improvement Program (NSQIP)
37%
Postoperative Complications
34%
Breast Reconstruction
27%
Postmastectomy Breast Reconstruction
27%
Postoperative Outcomes
27%
Projected Database
24%
Medical Complications
23%
Comorbidity
23%
Postmastectomy
21%
Complication Rate
18%
Fibroepithelial
18%
Mortality Prediction
18%
Tumor Size
18%
American College of Surgeons
18%
Complications of Therapy
18%
AIDS/HIV
18%
Chemotherapy
18%
Breast-conserving Therapy
18%
Myoid Hamartoma
18%
Urban Population
18%
Breast Core Needle Biopsy
18%
COVID-19
18%
Prognostic Factors
18%
HER2+ Breast Cancer
18%
MFI-5
18%
Hazard Ratio
18%
Oncological Safety
18%
National Cancer Database
18%
Breast Cancer Outcomes
18%
Imaging Modalities
18%
Venous Infarction
18%
Nipple-sparing Mastectomy
18%
Immediate Reconstruction
18%
Excision
18%
Surgical Complications
18%
Comparative Analysis
18%
Multidisciplinary Approach
18%
Radiation Complications
18%
Phyllodes Tumor
18%
Trend Analysis
18%
Male Patients
18%
Patient Demographics
18%
Paucity
16%
Total Mastectomy
16%
HER2+
15%
Coagulopathy
13%
Medicine and Dentistry
Breast Cancer
100%
Mastectomy
64%
Male Breast Cancer
55%
Postoperative Complication
46%
Breast Reconstruction
46%
Quality Improvement
37%
Neoplasm
29%
Malignant Neoplasm
26%
Recurrent Disease
26%
Simple Mastectomy
19%
Needle Biopsy
18%
Frailty
18%
Disease
18%
Hazard Ratio
18%
Human Immunodeficiency Virus
18%
Human Epidermal Growth Factor Receptor 2 Positive Breast Cancer
18%
Triple Negative Breast Cancer
18%
Hamartoma
18%
Urban Population
18%
Clinical Management
18%
Surgeon
18%
Coronavirinae
18%
Phyllodes Tumor
18%
Infarction
18%
Body Mass Index
16%
Systematic Review
13%
Coagulopathy
13%
Overall Survival
10%
Mammography
10%
Risk Stratification
9%
Patient Satisfaction
9%
Neoadjuvant Chemotherapy
8%
Prevalence
8%
Magnetic Resonance Imaging
8%
Mammogram
8%
Prognostic Factor
7%
Echography
6%
Breast Surgery
6%
Retrospective Cohort Study
5%
Breast Carcinoma
5%
End Stage Renal Disease
5%
Oncology
5%
Systemic Therapy
5%
Metastatic Carcinoma
5%
Atrial Fibrillation
5%
Diabetes Mellitus
5%
Adjuvant Chemotherapy
5%